Skip to main content
. 2021 Jun 15;11(6):3227–3239.

Figure 2.

Figure 2

Overall survival (OS) of MTC patients with ATF4 loss. A. Overall survival based on somatic ATF4 copy number normal (2N) versus loss (0 or 1 copy). Log-rank test, *P=0.011. The median OS for patients with ATF4 copy number loss was 111.3 months (95% CI: 84.9 months to not reached), 2N: 2 copies of ATF4). B. Overall survival based on ATF4 protein levels (High ≥20% nuclear expression; Low, <20% nuclear expression) in primary tumors by immunohistochemical analysis. Log-rank test, **P<0.001. The median OS time for low ATF4 protein was 111.3 months (95% CI: 84.9 months to not reached). C. Overall survival of MTC patients according to somatic ATF4 copy number in combination with somatic RETM918T mutation status (RET neg negative for RETM918T mutation vs. RETM918T present; ATF4 loss (only one or no copies of ATF4). The median OS time for ATF42N/RETneg was not reached; the median OS for ATF4 loss/RETM918T was 87.7 (95% CI: 84.9-Not reached); the median OS for ATF4 loss /RETneg, was 111.3 (95% CI: 74.6-Not reached); the median OS time for ATF4 2N/RETM918T was 143.7 (95% CI: 107.5-Not reached)). Log-rank test, P=0.098. D. Overall survival based on ATF4 protein levels and somatic RETM918T mutation status. ATF4-High/RETneg, median OS time was not reached; the median OS time for ATF4-High/RETM918T was 143.7 (95% CI: 107.5-Not reached); the median OS time for low/RETM918T was 87.7 (95% CI: 31.4-Not reached) and the median OS time for low/RETneg was 113.3 (95% CI: 74.6-Not reached); Log-rank test, *P=0.01.